A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Phase 1 Completed 16 enrolled Vertex Pharmaceuticals Incorporated

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet (FDC) of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA).

Timeline

Start: 2022-09-15
Primary completion: 2022-11-09
Completion: 2022-11-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vanzacaftor	Small molecule	—	Oral

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Summary

Timeline

Drugs

Indications